Noriko Satake
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noriko Satake has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Yueju Li
Department of Public Health Sciences, UC Davis, Davis, California, USA
7 shared publicationsLaurel Beckett
Department of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States
6 shared publicationsConnie Duong
Department of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States
5 shared publicationsSakiko Yoshida
Department of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States
5 shared publicationsMasami Ijiri
Department of Pediatrics, UC Davis School of Medicine, Sacramento, California, USA
4 shared publicationsNitin Nitin
Department of Pediatrics, University of California (UC) Davis School of Medicine, Sacramento, CA, United States
4 shared publications
Latest Publications
- Open Access
Targeting CDK11 in Rhabdoid Tumor of the Kidney
Background: Rhabdoid tumor of the kidney (RTK) is a highly aggressive pediatric malignancy characterized by biallelic SMARCB1 loss, resulting in aberrant MYC pathway activation and cell cycle regulation. MYC-activated tumors are vulnerable in splicing functions and sensitive to splicing inhibitors. Therefore, in this study, cyclin-dependent kinase 11 (CDK11), which regulates both cell cycle and RNA splicing, was tested as a therapeutic target in RTK. Methods: CDK11A/B expression was analyzed using the TARGET-RT database. The therapeutic efficacy of the CDK11 inhibitor OTS964 was evaluated in two RTK cell lines (G401 and JMU-RTK-2) and a JMU-RTK-2 xenograft mouse model. Cytotoxicity, apoptosis, cell cycle, and RNA splicing were examined using the Sulforhodamine B assay, immunoblotting, flow cytometry, and RT-PCR. Results: CDK11B, but not CDK11A, was significantly upregulated in RTK and correlated with the poor survival. OTS964 inhibited RTK cell growth in vitro with the IC50 of 33.1 nM (G401) and 19.3 nM (JMU-RTK-2) and significantly prolonged survival in vivo (median survival: 46.5 vs. 37.0 days, p < 0.01) without marked toxicity. Mechanistically, OTS964 induced G2/M cell cycle arrest and p53 upregulation, disrupted RNA splicing via SF3B1 dephosphorylation, and ultimately led to apoptosis through caspase-3 activation. Conclusions: CDK11 inhibition by OTS964 effectively suppresses RTK growth through cell cycle arrest and RNA splicing inhibition, leading to apoptosis. OTS964 shows potent anti-tumor activity and tolerability, supporting CDK11 as a promising therapeutic target for RTK and related SMARCB1-deficient cancers.
Open AccessTargeting CDK11 in Rhabdoid Tumor of the Kidney
Background: Rhabdoid tumor of the kidney (RTK) is a highly aggressive pediatric malignancy characterized by biallelic SMARCB1 loss, resulting in aberrant MYC pathway activation and cell cycle regulation. MYC-activated tumors are vulnerable in splicing functions and sensitive to splicing inhibitors. Therefore, in this study, cyclin-dependent kinase 11 (CDK11), which regulates both cell cycle and RNA splicing, was tested as a therapeutic target in RTK. Methods: CDK11A/B expression was analyzed using the TARGET-RT database. The therapeutic efficacy of the CDK11 inhibitor OTS964 was evaluated in two RTK cell lines (G401 and JMU-RTK-2) and a JMU-RTK-2 xenograft mouse model. Cytotoxicity, apoptosis, cell cycle, and RNA splicing were examined using the Sulforhodamine B assay, immunoblotting, flow cytometry, and RT-PCR. Results: CDK11B, but not CDK11A, was significantly upregulated in RTK and correlated with the poor survival. OTS964 inhibited RTK cell growth in vitro with the IC50 of 33.1 nM (G401) and 19.3 nM (JMU-RTK-2) and significantly prolonged survival in vivo (median survival: 46.5 vs. 37.0 days, p < 0.01) without marked toxicity. Mechanistically, OTS964 induced G2/M cell cycle arrest and p53 upregulation, disrupted RNA splicing via SF3B1 dephosphorylation, and ultimately led to apoptosis through caspase-3 activation. Conclusions: CDK11 inhibition by OTS964 effectively suppresses RTK growth through cell cycle arrest and RNA splicing inhibition, leading to apoptosis. OTS964 shows potent anti-tumor activity and tolerability, supporting CDK11 as a promising therapeutic target for RTK and related SMARCB1-deficient cancers.
- Open Access
- 21 November 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8  (1) , e50710
Health Perceptions and Practices of a Telewellness Fitness Program: Exploratory Case Study
Background: During the COVID-19 pandemic, many people lacked access to group fitness opportunities due to elevated risk of infection, lockdown, and closure of exercise facilities. Additionally, many people experienced higher than average rates of mental health burden (eg, anxiety and stress). To help address these needs, an existing in-person community exercise class, taught by a faculty member from an academic medical center, transitioned to an online synchronous (OS) physical fitness class via the Zoom (Zoom Video Communications) videoconferencing platform. As such, the instructor advertised the OS fitness classes through an existing email list of community members and university faculty, staff, students, or alumni email listservs. This telewellness intervention sought to create a sense of community, build social support, and promote physical and mental wellness during the COVID-19 pandemic. Objective: Our aim was to determine the perceived mental and physical health benefits of attending an OS fitness class for community members, including health care workers. We also assessed the use and functionality of related technologies necessary for delivering and attending the fitness classes. Methods: An online survey questionnaire was created and tested to collect quantitative and qualitative data for an exploratory study. Data were collected to evaluate the fitness class, motivation, perceived health benefits, and related technologies. A convenience sample of people who had participated in the OS fitness classes was recruited for this study via an emailed recruitment flyer. Results: A total of 51 participants accessed and completed the survey questionnaire. Survey participants consisted of 28 of 51 (55%) with a university affiliation, 17 of 51 (33%) with no university affiliation, and 6 of 51 (12%) who declined to state. The largest group of participants reporting full-time employment (18/51, 35%) also reported university affiliation with the academic medical center. In this group, 13 of 51 (25%) participants reported full-time employment, university affiliation, and doctoral degrees. High overall exercise class satisfaction was observed in the survey responses (mean 4.0, SD 1). Data analyses revealed significant perceived value of both mental and physical health benefits as motivating factors for participating in the OS fitness class. Challenges were identified as not being able to receive individual feedback from the instructor and the inability of some participants to see if they were in sync with the rest of the class. Conclusions: Results provide preliminary support for the use of online videoconferencing fitness platforms to promote wellness and facilitate group exercise in the community during times of high infection risk. Future studies should continue to explore perceived benefits, mental and physical wellness, best practices, and the design of related technologies.
- 21 November 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8  (1) , e50710
Open AccessHealth Perceptions and Practices of a Telewellness Fitness Program: Exploratory Case Study
Background: During the COVID-19 pandemic, many people lacked access to group fitness opportunities due to elevated risk of infection, lockdown, and closure of exercise facilities. Additionally, many people experienced higher than average rates of mental health burden (eg, anxiety and stress). To help address these needs, an existing in-person community exercise class, taught by a faculty member from an academic medical center, transitioned to an online synchronous (OS) physical fitness class via the Zoom (Zoom Video Communications) videoconferencing platform. As such, the instructor advertised the OS fitness classes through an existing email list of community members and university faculty, staff, students, or alumni email listservs. This telewellness intervention sought to create a sense of community, build social support, and promote physical and mental wellness during the COVID-19 pandemic. Objective: Our aim was to determine the perceived mental and physical health benefits of attending an OS fitness class for community members, including health care workers. We also assessed the use and functionality of related technologies necessary for delivering and attending the fitness classes. Methods: An online survey questionnaire was created and tested to collect quantitative and qualitative data for an exploratory study. Data were collected to evaluate the fitness class, motivation, perceived health benefits, and related technologies. A convenience sample of people who had participated in the OS fitness classes was recruited for this study via an emailed recruitment flyer. Results: A total of 51 participants accessed and completed the survey questionnaire. Survey participants consisted of 28 of 51 (55%) with a university affiliation, 17 of 51 (33%) with no university affiliation, and 6 of 51 (12%) who declined to state. The largest group of participants reporting full-time employment (18/51, 35%) also reported university affiliation with the academic medical center. In this group, 13 of 51 (25%) participants reported full-time employment, university affiliation, and doctoral degrees. High overall exercise class satisfaction was observed in the survey responses (mean 4.0, SD 1). Data analyses revealed significant perceived value of both mental and physical health benefits as motivating factors for participating in the OS fitness class. Challenges were identified as not being able to receive individual feedback from the instructor and the inability of some participants to see if they were in sync with the rest of the class. Conclusions: Results provide preliminary support for the use of online videoconferencing fitness platforms to promote wellness and facilitate group exercise in the community during times of high infection risk. Future studies should continue to explore perceived benefits, mental and physical wellness, best practices, and the design of related technologies.
- Open Access
- 22 April 2024
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41  (5) , 367-375
Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric leukemia with few effective treatments and poor outcomes even after stem cell transplantation, the only current curative treatment. We developed a JMML patient-derived xenograft (PDX) mouse model and demonstrated the in vivo therapeutic efficacy and confirmed the target of trametinib, a RAS-RAF-MEK-ERK pathway inhibitor, in this model. A PDX model was created through transplantation of patient JMML cells into mice, up to the second generation, and successful engraftment was confirmed using flow cytometry. JMML PDX mice were treated with trametinib versus vehicle control, with a median survival of 194 days in the treatment group versus 124 days in the control group (p = 0.02). Trametinib's target as a RAS pathway inhibitor was verified by showing inhibition of ERK phosphorylation using immunoblot assays. In conclusion, trametinib monotherapy significantly prolongs survival in our JMML PDX model by inhibiting the RAS pathway. Our model can be effectively used for assessment of novel targeted treatments, including potential combination therapies, to improve JMML outcomes.
- 22 April 2024
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41  (5) , 367-375
Open AccessTherapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric leukemia with few effective treatments and poor outcomes even after stem cell transplantation, the only current curative treatment. We developed a JMML patient-derived xenograft (PDX) mouse model and demonstrated the in vivo therapeutic efficacy and confirmed the target of trametinib, a RAS-RAF-MEK-ERK pathway inhibitor, in this model. A PDX model was created through transplantation of patient JMML cells into mice, up to the second generation, and successful engraftment was confirmed using flow cytometry. JMML PDX mice were treated with trametinib versus vehicle control, with a median survival of 194 days in the treatment group versus 124 days in the control group (p = 0.02). Trametinib's target as a RAS pathway inhibitor was verified by showing inhibition of ERK phosphorylation using immunoblot assays. In conclusion, trametinib monotherapy significantly prolongs survival in our JMML PDX model by inhibiting the RAS pathway. Our model can be effectively used for assessment of novel targeted treatments, including potential combination therapies, to improve JMML outcomes.
- Open Access
- 12 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Exploring Telewellness: A Mixed-Method Approach to Health Perceptions and Practices of a Livestream Virtual Fitness Class (Preprint)
BACKGROUND During early COVID-19, employees, and community members lacked access to fitness classes due to the elevated risk of infection and access to exercise facilities. An online, synchronous, physical fitness class was delivered via videoconferencing to create a sense of community and promote physical and mental wellness among healthcare workers and community members. Participants were recruited via faculty/staff listservs and instructor email list. Classes were taught by a faculty member at an academic medical center. OBJECTIVE This study examines the perceived mental and physical health benefits of attending an online, synchronous, physical fitness class for healthcare workers and community members. We also assess the feasibility and functionality of related technologies necessary for delivering and attending livestream fitness classes. METHODS Descriptive data were collected using an online participant survey that included quantitative and qualitative analyses to evaluate the ongoing, online exercise class. These data were collected via one survey during November and December of 2022. RESULTS 51 participants were recruited and 100% completed the participant questionnaire. Survey participants consisted of 28 employees (55%), 17 non-employees (33%), and 6 declined to state (12%). High overall exercise class satisfaction was observed in the survey responses (mean 4.0 out of 5, SD=1). Survey analyses revealed significant perceived value of mental and physical health benefits as motivating factors for taking livestreamed physical fitness class. CONCLUSIONS Results provide preliminary support for the use of online videoconferencing platforms to facilitate synchronous fitness classes for employees and associated community members. Future studies should continue to explore perceived benefits, including mental and physical wellness.
- 12 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessExploring Telewellness: A Mixed-Method Approach to Health Perceptions and Practices of a Livestream Virtual Fitness Class (Preprint)
BACKGROUND During early COVID-19, employees, and community members lacked access to fitness classes due to the elevated risk of infection and access to exercise facilities. An online, synchronous, physical fitness class was delivered via videoconferencing to create a sense of community and promote physical and mental wellness among healthcare workers and community members. Participants were recruited via faculty/staff listservs and instructor email list. Classes were taught by a faculty member at an academic medical center. OBJECTIVE This study examines the perceived mental and physical health benefits of attending an online, synchronous, physical fitness class for healthcare workers and community members. We also assess the feasibility and functionality of related technologies necessary for delivering and attending livestream fitness classes. METHODS Descriptive data were collected using an online participant survey that included quantitative and qualitative analyses to evaluate the ongoing, online exercise class. These data were collected via one survey during November and December of 2022. RESULTS 51 participants were recruited and 100% completed the participant questionnaire. Survey participants consisted of 28 employees (55%), 17 non-employees (33%), and 6 declined to state (12%). High overall exercise class satisfaction was observed in the survey responses (mean 4.0 out of 5, SD=1). Survey analyses revealed significant perceived value of mental and physical health benefits as motivating factors for taking livestreamed physical fitness class. CONCLUSIONS Results provide preliminary support for the use of online videoconferencing platforms to facilitate synchronous fitness classes for employees and associated community members. Future studies should continue to explore perceived benefits, including mental and physical wellness.
- Open Access
- 10 July 2023
- Published by Association for Computing Machinery (ACM)
- p. 261-265
ZoombaTogether: A Video Conference Add-on for Generating Interactive Visual Feedback for Online Group Exercise Through On-The-Fly Pose Tracking
Exercise benefits people not only in physical health but also in mental health. Compared to individual workouts, many people prefer group exercise because of the additional peer support like guidance from experienced peers, and socializing benefits like the opportunities to meet new friends when exercising with others as a group. However, during the pandemic, many group exercise sessions were shifted from in-person to online through video conferencing platforms. Such change significantly decreased the exercise feedback and social signals that participants could receive during the exercise, such as the immediate self-checking with a studio mirror, the group movement calibration with co-exercisers, and the sense of social presence (i.e., the existence of other co-exercisers) in the small community. To address these challenges, we present ZoombaTogether, a video platform add-on that enhances the remote Zumba dancing experience with on-the-fly pose detection and visualization techniques. It tracks and evaluates how well remote dancers follow the instructor with minor latency and provide them with visual feedback to simulate a joint exercise experience with group members. ZoombaTogether visualizes the participants’ performance at both individual and group levels to help them understand their movement similarity to the instructor and other dancers with a set of extensible visualization modules. Meanwhile, ZoombaTogether addresses the participants’ privacy concerns by supporting on-device computer vision-based body posture estimation so that they could keep their personal video private from other group members. In this work, we provide a solution to use visual feedback as a communication channel for exercise participants and demonstrate the possibility of enhancing the online group exercise experience. We encourage the community to carry on our work and explore solutions to the challenges of missing social signals in online group exercises.
- 10 July 2023
- Published by Association for Computing Machinery (ACM)
- p. 261-265
Open AccessZoombaTogether: A Video Conference Add-on for Generating Interactive Visual Feedback for Online Group Exercise Through On-The-Fly Pose Tracking
Exercise benefits people not only in physical health but also in mental health. Compared to individual workouts, many people prefer group exercise because of the additional peer support like guidance from experienced peers, and socializing benefits like the opportunities to meet new friends when exercising with others as a group. However, during the pandemic, many group exercise sessions were shifted from in-person to online through video conferencing platforms. Such change significantly decreased the exercise feedback and social signals that participants could receive during the exercise, such as the immediate self-checking with a studio mirror, the group movement calibration with co-exercisers, and the sense of social presence (i.e., the existence of other co-exercisers) in the small community. To address these challenges, we present ZoombaTogether, a video platform add-on that enhances the remote Zumba dancing experience with on-the-fly pose detection and visualization techniques. It tracks and evaluates how well remote dancers follow the instructor with minor latency and provide them with visual feedback to simulate a joint exercise experience with group members. ZoombaTogether visualizes the participants’ performance at both individual and group levels to help them understand their movement similarity to the instructor and other dancers with a set of extensible visualization modules. Meanwhile, ZoombaTogether addresses the participants’ privacy concerns by supporting on-device computer vision-based body posture estimation so that they could keep their personal video private from other group members. In this work, we provide a solution to use visual feedback as a communication channel for exercise participants and demonstrate the possibility of enhancing the online group exercise experience. We encourage the community to carry on our work and explore solutions to the challenges of missing social signals in online group exercises.
- Open Access
- 5 January 2023
- Published by Elsevier in Experimental Hematology
- Vol. 119-120, 8-13.e1
Cmpd10357 to treat B-cell acute lymphoblastic leukemia
- 5 January 2023
- Published by Elsevier in Experimental Hematology
- Vol. 119-120, 8-13.e1
Open AccessCmpd10357 to treat B-cell acute lymphoblastic leukemia
- Open Access
- 21 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 972323
A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile
In leukemia, a distinct subpopulation of cancer-initiating cells called leukemia stem cells (LSCs) is believed to drive population expansion and tumor growth. Failing to eliminate LSCs may result in disease relapse regardless of the amount of non-LSCs destroyed. The first step in targeting and eliminating LSCs is to identify and characterize them. Acute precursor B lymphoblastic leukemia (B-ALL) cells derived from patients were incubated with fluorescent glucose analog 2-(N-(7-Nitrobenz-2-oxa-1, 3-diazol-4-yl) Amino)-2-Deoxyglucose (NBDG) and sorted based on NBDG uptake. Cell subpopulations defined by glucose uptake were then serially transplanted into mice and evaluated for leukemia initiating capacity. Gene expression profiles of these cells were characterized using RNA-Sequencing (RNA-Seq). A distinct population of NBDG-low cells was identified in patient B-ALL samples. These cells are a small population (1.92% of the entire leukemia population), have lower HLA expression, and are smaller in size (4.0 to 7.0 μm) than the rest of the leukemia population. All mice transplanted with NBDG-low cells developed leukemia between 5 and 14 weeks, while those transplanted with NBDG-high cells did not develop leukemia (p ≤ 0.0001-0.002). Serial transplantation of the NBDG-low mouse model resulted in successful leukemia development. NBDG-medium (NBDG-med) populations also developed leukemia. Interestingly, comprehensive molecular characterization of NBDG-low and NBDG-med cells from patient-derived xenograft (PDX) models using RNA-Seq revealed a distinct profile of 2,162 differentially-expressed transcripts (DETs) (pin vivo, showing leukemia initiating capacity. Our study provides insight into the biologic mechanisms of B-ALL initiation and survival.
- 21 September 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 972323
Open AccessA distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile
In leukemia, a distinct subpopulation of cancer-initiating cells called leukemia stem cells (LSCs) is believed to drive population expansion and tumor growth. Failing to eliminate LSCs may result in disease relapse regardless of the amount of non-LSCs destroyed. The first step in targeting and eliminating LSCs is to identify and characterize them. Acute precursor B lymphoblastic leukemia (B-ALL) cells derived from patients were incubated with fluorescent glucose analog 2-(N-(7-Nitrobenz-2-oxa-1, 3-diazol-4-yl) Amino)-2-Deoxyglucose (NBDG) and sorted based on NBDG uptake. Cell subpopulations defined by glucose uptake were then serially transplanted into mice and evaluated for leukemia initiating capacity. Gene expression profiles of these cells were characterized using RNA-Sequencing (RNA-Seq). A distinct population of NBDG-low cells was identified in patient B-ALL samples. These cells are a small population (1.92% of the entire leukemia population), have lower HLA expression, and are smaller in size (4.0 to 7.0 μm) than the rest of the leukemia population. All mice transplanted with NBDG-low cells developed leukemia between 5 and 14 weeks, while those transplanted with NBDG-high cells did not develop leukemia (p ≤ 0.0001-0.002). Serial transplantation of the NBDG-low mouse model resulted in successful leukemia development. NBDG-medium (NBDG-med) populations also developed leukemia. Interestingly, comprehensive molecular characterization of NBDG-low and NBDG-med cells from patient-derived xenograft (PDX) models using RNA-Seq revealed a distinct profile of 2,162 differentially-expressed transcripts (DETs) (pin vivo, showing leukemia initiating capacity. Our study provides insight into the biologic mechanisms of B-ALL initiation and survival.
- Open Access
- 26 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
Background: Renal medullary carcinoma (RMC) is a rare but aggressive tumor often complicated by early lung metastasis with few treatment options and very poor outcomes. There are currently no verified RMC patient-derived xenograft (PDX) mouse models established from metastatic pleural effusion (PE) available to study RMC and evaluate new therapeutic options.Methods: Renal tumor tissue and malignant PE cells from an RMC patient were successfully engrafted into 20 NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. We evaluated the histopathological similarity of the renal tumor and PE PDXs with the original patient renal tumor and PE, respectively. We then evaluated the molecular integrity of the renal tumor PDXs between passages, as well as the PE PDX compared to two generations of renal tumor PDXs, by microarray analysis. The therapeutic efficacy of sunitinib and temsirolimus was tested in a serially-transplanted generation of 27 PE PDX mice.Results: The pathologic characteristics of the patient renal tumor and patient PE were retained in the PDXs. Gene expression profiling revealed high concordance between the two generations of renal tumor PDXs (RMC-P0 vs. RMC-P1, r=0.865), as well as between the first generation PE PDX and each generation of the renal tumor PDX (PE-P0 vs. RMC-P0, r=0.919 and PE-P0 vs. RMC-P1, r=0.843). A low number (626) of differentially-expressed genes (DEGs) was seen between the first generation PE PDX and the first generation renal tumor PDX. In the PE-P1 xenograft, sunitinib significantly reduced tumor growth (p<0.001) and prolonged survival (p=0.004) compared to the vehicle control.Conclusions: A metastatic PE-derived RMC PDX model was established and shown to maintain histologic features of the patient cancer. Molecular integrity of the PDX models was well maintained between renal tumor and PE PDX as well as between two successive renal tumor PDX generations. Using the PE PDX model, sunitinib demonstrated therapeutic efficacy for RMC. This model can serve as a foundation for future mechanistic and therapeutic studies for primary and metastatic RMC.
- 26 March 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessNovel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib
Background: Renal medullary carcinoma (RMC) is a rare but aggressive tumor often complicated by early lung metastasis with few treatment options and very poor outcomes. There are currently no verified RMC patient-derived xenograft (PDX) mouse models established from metastatic pleural effusion (PE) available to study RMC and evaluate new therapeutic options.Methods: Renal tumor tissue and malignant PE cells from an RMC patient were successfully engrafted into 20 NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. We evaluated the histopathological similarity of the renal tumor and PE PDXs with the original patient renal tumor and PE, respectively. We then evaluated the molecular integrity of the renal tumor PDXs between passages, as well as the PE PDX compared to two generations of renal tumor PDXs, by microarray analysis. The therapeutic efficacy of sunitinib and temsirolimus was tested in a serially-transplanted generation of 27 PE PDX mice.Results: The pathologic characteristics of the patient renal tumor and patient PE were retained in the PDXs. Gene expression profiling revealed high concordance between the two generations of renal tumor PDXs (RMC-P0 vs. RMC-P1, r=0.865), as well as between the first generation PE PDX and each generation of the renal tumor PDX (PE-P0 vs. RMC-P0, r=0.919 and PE-P0 vs. RMC-P1, r=0.843). A low number (626) of differentially-expressed genes (DEGs) was seen between the first generation PE PDX and the first generation renal tumor PDX. In the PE-P1 xenograft, sunitinib significantly reduced tumor growth (p<0.001) and prolonged survival (p=0.004) compared to the vehicle control.Conclusions: A metastatic PE-derived RMC PDX model was established and shown to maintain histologic features of the patient cancer. Molecular integrity of the PDX models was well maintained between renal tumor and PE PDX as well as between two successive renal tumor PDX generations. Using the PE PDX model, sunitinib demonstrated therapeutic efficacy for RMC. This model can serve as a foundation for future mechanistic and therapeutic studies for primary and metastatic RMC.
- 1 February 2020
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 24, 102127
MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: A new targeted approach for neuroblastoma
- 1 February 2020
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 24, 102127
MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: A new targeted approach for neuroblastoma
- Open Access
- 31 May 2017
- Published by Springer Nature in Pediatric Research
- Vol. 82  (3) , 527-535
Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA
Neuroblastoma is the second most common extracranial cancer in children. Current therapies for neuroblastoma, which use a combination of chemotherapy drugs, have limitations for high-risk subtypes and can cause significant long-term adverse effects in young patients. Therefore, a new therapy is needed. In this study, we investigated the transcription factor MXD3 as a potential therapeutic target in neuroblastoma. MXD3 expression was analyzed in five neuroblastoma cell lines by immunocytochemistry and quantitative real-time reverse transcription PCR, and in 18 primary patient tumor samples by immunohistochemistry. We developed nanocomplexes using siRNA and superparamagnetic iron oxide nanoparticles to target MXD3 in neuroblastoma cell lines in vitro as a single-agent therapeutic and in combination with doxorubicin, vincristine, cisplatin, or maphosphamide—common drugs used in current neuroblastoma treatment. MXD3 was highly expressed in neuroblastoma cell lines and in patient tumors that had high-risk features. Neuroblastoma cells treated in vitro with the MXD3 siRNA nanocomplexes showed MXD3 protein knockdown and resulted in cell apoptosis. Furthermore, on combining MXD3 siRNA nanocomplexes with each of the four drugs, all showed additive efficacy. These results indicate that MXD3 is a potential new target and that the use of MXD3 siRNA nanocomplexes is a novel therapeutic approach for neuroblastoma.
- 31 May 2017
- Published by Springer Nature in Pediatric Research
- Vol. 82  (3) , 527-535
Open AccessNovel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA
Neuroblastoma is the second most common extracranial cancer in children. Current therapies for neuroblastoma, which use a combination of chemotherapy drugs, have limitations for high-risk subtypes and can cause significant long-term adverse effects in young patients. Therefore, a new therapy is needed. In this study, we investigated the transcription factor MXD3 as a potential therapeutic target in neuroblastoma. MXD3 expression was analyzed in five neuroblastoma cell lines by immunocytochemistry and quantitative real-time reverse transcription PCR, and in 18 primary patient tumor samples by immunohistochemistry. We developed nanocomplexes using siRNA and superparamagnetic iron oxide nanoparticles to target MXD3 in neuroblastoma cell lines in vitro as a single-agent therapeutic and in combination with doxorubicin, vincristine, cisplatin, or maphosphamide—common drugs used in current neuroblastoma treatment. MXD3 was highly expressed in neuroblastoma cell lines and in patient tumors that had high-risk features. Neuroblastoma cells treated in vitro with the MXD3 siRNA nanocomplexes showed MXD3 protein knockdown and resulted in cell apoptosis. Furthermore, on combining MXD3 siRNA nanocomplexes with each of the four drugs, all showed additive efficacy. These results indicate that MXD3 is a potential new target and that the use of MXD3 siRNA nanocomplexes is a novel therapeutic approach for neuroblastoma.